Suppression of CEP55 reduces cell viability and induces apoptosis in human lung cancer

Ligang Liu1, Qi Mei2, Jing Zhao2

  • 1Department of Cardiothoracic Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, P.R. China.

Oncology Reports
|September 17, 2016
PubMed

Insights

Centrosomal protein 55 (CEP55) is elevated in lung cancer, promoting tumor cell growth and proliferation. Inhibiting CEP55 may offer a new therapeutic strategy for lung cancer treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Biology

Background:

  • Centrosomal protein 55 (CEP55) is linked to human malignancies.
  • The specific role of CEP55 in lung cancer pathogenesis is not well understood.

Purpose of the Study:

  • To investigate the expression and function of CEP55 in human lung cancer.
  • To explore the potential of CEP55 as a therapeutic target for lung cancer.

Main Methods:

  • Quantitative RT-PCR to analyze CEP55 mRNA expression in lung cancer tissues.
  • Loss-of-function assays (siRNA) in lung cancer cell lines (A549, 95D).
  • Cell viability (MTT), proliferation (colony formation), cell cycle, apoptosis (flow cytometry), and Western blot analyses.

Main Results:

  • CEP55 mRNA levels were significantly higher in lung cancer tissues compared to adjacent non-tumor tissues.
  • CEP55 knockdown inhibited lung cancer cell viability and proliferation.
  • CEP55 silencing induced G0/G1 cell cycle arrest and increased apoptosis.
  • CEP55 knockdown altered the expression of key cell cycle regulators (CDK4, p21) and apoptosis markers (Bcl-2, Bad, caspase-3, PARP).

Conclusions:

  • CEP55 plays a critical role in promoting lung cancer cell proliferation in vitro.
  • Targeting CEP55 could represent a novel therapeutic strategy for lung cancer.